Search giant Google last year formed a company focused on tackling aging and other associated diseases, and now Sony is upping its commitment to breakthrough medicine after it announced a joint venture focused on advancing medical research using genetics in Japan.
Sony is forming a new company to focus on genome research with a view towards realizing personalized medicine and healthcare. The venture, currently called P5 Inc, is a collaboration with M3, a medical company in which Sony is the majority stakeholder, and Illumina, a US-based manufacturer of genome-sequencing equipment. News of the tie-up between Sony and Illumina, which will be a minority investor, was first reported by Jiji Press last year. Sony refers to the collaboration as a “genome information platform.” It will provide genome analysis services for enterprises and research institutions in Japan at first, as well as aggregating genetic data with other medical data.
NOTE: TECHi Two-Takes are the stories we have chosen from the web along with a little bit of our opinion in a paragraph. Please check the original story in the Source Button below.
TECHi weighs both sides before reaching a conclusion.
TECHi’s editorial take above outlines the reasoning that supports this position.
Microsoft's Copilot AI in Windows 11 falls short of user expectations, especially when compared to the company’s high-profile advertisements. Real-world…
Apple's idea to use OLED screens for gadgets shows how keen they are to boost how things look and feel.…
The Pixel Watch 4 is a new milestone in the world of smartwatches offered by Google. It brings several firsts,…
This most recent leak of Apple has got everybody talking in the tech world. The emerging code suggests substantial updates…
